Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: rowland k. Dermatol Ther (Heidelb). 2023 Feb;13(2):629-640. doi: 10.1007/s13555-022-00879-8. Epub 2022 Dec 31. Dermatol Ther (Heidelb). 2023. PMID: 36585606 Free PMC article.
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF. Walsh JA, et al. Among authors: rowland k. Dermatol Ther (Heidelb). 2022 Jan;12(1):97-119. doi: 10.1007/s13555-021-00637-2. Epub 2021 Nov 25. Dermatol Ther (Heidelb). 2022. PMID: 34822121 Free PMC article.
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: rowland k. Dermatol Ther (Heidelb). 2023 Feb;13(2):487-504. doi: 10.1007/s13555-022-00865-0. Epub 2022 Dec 9. Dermatol Ther (Heidelb). 2023. PMID: 36484917 Free PMC article.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA. Blauvelt A, et al. Among authors: rowland k. J Am Acad Dermatol. 2023 Aug;89(2):274-282. doi: 10.1016/j.jaad.2023.03.035. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019386 Free article.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Strober B, et al. Among authors: rowland k. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. Drug Saf. 2024. PMID: 37906417 Free PMC article. Clinical Trial.
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).
Rapp SR, Dressler EV, Brown WM, Wade JL 3rd, Le-Lindqwister N, King D, Rowland KM, Weaver KE, Klepin HD, Shaw EG, Lesser GJ. Rapp SR, et al. Among authors: rowland km. J Clin Oncol. 2024 May 6:JCO2301100. doi: 10.1200/JCO.23.01100. Online ahead of print. J Clin Oncol. 2024. PMID: 38709986
Nutrition: Foreword.
Rowland K. Rowland K. FP Essent. 2024 Apr;539:2. FP Essent. 2024. PMID: 38648168 No abstract available.
342 results